ChiCTR2400086784 版本V1.1 版本创建时间2024/07/10 17:07:22 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400086784 

最近更新日期:

Date of Last Refreshed on:

2024-07-10 17:07:14 

注册时间:

Date of Registration:

2024-07-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于肠道微生态探讨雷火灸对盆腔肿瘤放疗后急性放射性肠炎临床疗效影响的研究

Public title:

Study on the effect of thunder-fire moxibustion on the clinical effect of acute radiation enteritis after pelvic tumor radiotherapy based on intestinal microecology

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于肠道微生态探讨雷火灸对盆腔肿瘤放疗后急性放射性肠炎临床疗效影响的研究

Scientific title:

Study on the effect of thunder-fire moxibustion on the clinical effect of acute radiation enteritis after pelvic tumor radiotherapy based on intestinal microecology

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王培 

研究负责人:

王培 

Applicant:

Pei Wang  

Study leader:

Pei Wang  

申请注册联系人电话:

Applicant telephone:

+86 150 0123 5023

研究负责人电话:

Study leader's telephone:

+86 150 0123 5023

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xiaopei349550779@126.com

研究负责人电子邮件:

Study leader's E-mail:

xiaopei349550779@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市通州区新华南路82号

研究负责人通讯地址:

北京市通州区新华南路82号

Applicant address:

No.82, Xinhua south street, Tongzhou Distract, Beijing, China.

Study leader's address:

No.82, Xinhua south street, Tongzhou Distract, Beijing 101199, China.

申请注册联系人邮政编码:

Applicant postcode:

101199

研究负责人邮政编码:

Study leader's postcode:

101199

申请人所在单位:

首都医科大学附属北京潞河医院

Applicant's institution:

Beijing Luhe hospital Affiliated to Capital Medical University

研究负责人所在单位:

首都医科大学附属北京潞河医院

Affiliation of the Leader:

Beijing Luhe hospital Affiliated to Capital Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-HLKY-054-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京潞河医院医学伦理委员会

Name of the ethic committee:

Medical ethics committee of Beijing Luhe hospital Affiliated to Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-06-17 00:00:00

伦理委员会联系人:

李海燕

Contact Name of the ethic committee:

Hai-yan Li

伦理委员会联系地址:

北京市通州区新华南路82号

Contact Address of the ethic committee:

No.82, Xinhua south street, Tongzhou Distract, Beijing, China.

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6056 9362

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京潞河医院

Primary sponsor:

Beijing Luhe hospital Affiliated to Capital Medical University

研究实施负责(组长)单位地址:

北京市通州区新华南路82号

Primary sponsor's address:

No.82, Xinhua south street, Tongzhou Distract, Beijing, China.

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

北京市

Country:

China

Province:

Beijing

City:

Beijing

单位(医院):

北京市卫生健康委员会

具体地址:

北京市通州区达济街6号院

Institution
hospital:

Beijing Municipal Commission of Health

Address:

Courtyard 6, Daji Street, Tongzhou District, Beijing

经费或物资来源:

北京市卫生健康委员会

Source(s) of funding:

Beijing Municipal Commission of Health

Target disease:

acute radiation enteritis after pelvic tumor radiotherapy

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.1通过对82例盆腔肿瘤放疗后急性放射性肠炎(Acute Radiation Enteritis,ARE)患者进行随机对照试验,探讨雷火灸对患者临床有效率、肠道损伤分级、中医证候积分及卡氏功能状态评分(KPS)等指标的影响,评估该方法对盆腔肿瘤放疗后ARE患者的临床疗效。 1.2通过肠道菌群检测,记录粪便中细菌微生物多样性的分布情况,对患者肠道微生态进行客观分析,以评价雷火灸对盆腔肿瘤放疗后ARE患者肠道菌群的影响,为优化首都地区盆腔肿瘤放疗后ARE的治疗方案提供科学依据。  

Objectives of Study:

1. 1 Through the randomized control trial of 82 patients of acute radiation enteritis (Acute Radiation Enteritis, ARE), to explore the influence of ray fire moxibustion in patients with clinical efficiency, intestinal injury grade, TCM syndrome and function status score (KPS), and evaluate the clinical efficacy of this method in patients with ARE after pelvic tumor radiotherapy. 1. 2 Through the detection of intestinal flora, the distribution of bacterial microbial diversity in feces was recorded, and the intestinal microecology of patients was objectively analyzed to evaluate the effect of thunder fire moxibustion on the intestinal flora of ARE patients with radiation for pelvic tumors, so as to provide scientific basis for optimizing the treatment plan of ARE after radiotherapy for pelvic tumors in the capital region.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①年龄20-80岁;②符合急性放射性肠炎的诊断标准;③无重要器官功能障碍,无既往重大胃肠疾病病史;④预计生存期均大于3月以上;⑤KPS评分大于60分;⑥两周内无抗生素使用病史;⑦愿意合作并签署知情同意书。

Inclusion criteria

① Age 20-80 years; ② met the diagnostic criteria for acute radiation enteritis; ③ no important organ dysfunction, no previous history of major gastrointestinal disease; ④ expected survival of more than 3 months; ⑤ KPS score greater than 60; ⑥ no history of antibiotics within two weeks; ⑦ willing to cooperate and sign informed consent.

排除标准:

①有克罗恩病、溃疡性结肠炎等胃肠道疾病史者;②妊娠、哺乳期妇女;③出现肠梗阻、穿孔等急需手术者;④有严重的心脑血管、肺、肝、肾等基础疾病者;⑤磺胺类药物过敏者;⑥肠道造瘘患者;⑦对艾草严重过敏者。

Exclusion criteria:

① Patients with a history of gastrointestinal diseases such as Crohn's disease and ulcerative colitis; ② women with pregnancy and lactation; ③ with intestinal obstruction and perforation; ④ with severe underlying diseases such as cardiovascular, cerebrovascular, lung, liver and kidney; ⑤ sulfa allergy; ⑥; ⑦ with severe allergy to mugwort.

研究实施时间:

Study execute time:

From 2024-01-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-07-15 00:00:00 To 2026-12-31 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

41

Group:

Control group

Sample size:

干预措施:

柳氮磺嘧啶+整肠生口服治疗,柳氮磺嘧啶:0.5g/次,2次/日,口服;整肠生:0.5g/次,3次/日,口服。连续治疗8周,并随访4周。

干预措施代码:

Intervention:

Sulfasalazine + parisgut oral treatment

Intervention code:

组别:

试验组

样本量:

41

Group:

Intervention group

Sample size:

干预措施:

对照组的基础上给予雷火灸治疗,取穴:神阙、关元、足三里(双侧)。器材:雷火灸条(28mm×105mm,重庆赵氏雷火灸传统医药研究所生产)、艾灸盒。 操作方法:患者放疗前1h,嘱患者取仰卧位,暴露腹部及双侧小腿,将雷火灸条分别固定在4个单孔灸盒顶端的灸孔内,用酒精灯点燃灸条,固定在灸盒顶部,放置在相应的穴位上并固定,分别盖上毛巾,以无明显灸烟渗出为度。温灸30min,每15min取出吹灰一次,灸至皮肤发红,深部组织发热,局部汗出为度。每周治疗3次,连续8周,并随访4周。

干预措施代码:

Intervention:

Thunder-fire moxibustion treatment was given based on the control group

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

北京 

Country:

China 

Province:

Beijing 

City:

Beijing 

单位(医院):

首都医科大学附属北京潞河医院 

单位级别:

三级 

Institution
hospital:

Beijing Luhe hospital Affiliated to Capital Medical University

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

临床疗效评价

指标类型:

主要指标

Outcome:

Evaluation of clinical efficacy

Type:

Primary indicator

测量时间点:

入组前及入组后第4、8及12周结束时各评价一次

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道损伤分级

指标类型:

主要指标

Outcome:

Grading of intestinal injury

Type:

Primary indicator

测量时间点:

入组前及入组后第4、8及12周结束时各记录一次

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医症候积分

指标类型:

主要指标

Outcome:

Traditional Chinese medicine syndrome points

Type:

Primary indicator

测量时间点:

入组前及入组后第4、8及12周结束时各记录一次

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卡氏功能状态评分

指标类型:

主要指标

Outcome:

Karnofsky performance status, KPS

Type:

Primary indicator

测量时间点:

入组前及入组后第4、8及12周结束时各记录一次

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

粪便常规

指标类型:

次要指标

Outcome:

stool for routine

Type:

Secondary indicator

测量时间点:

入组前及入组后第8及12周结束时各检测一次

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道菌群

指标类型:

次要指标

Outcome:

intestinal flora

Type:

Secondary indicator

测量时间点:

入组前及入组后第8及12周结束时各检测一次

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

炎症指标

指标类型:

次要指标

Outcome:

Inflammatory indicators

Type:

Secondary indicator

测量时间点:

入组前及入组后第8及12周结束时各检测一次

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

excrement and urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由第三方不参与该研究的统计专业人员运用SPSS 24.0软件(SPSS Inc., Chicago, IL)生成随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

A third party not involved in the study generated a random number table by using SPSS 24. 0 software (SPSS Inc., Chicago, IL).

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

本研究将采用患者、操作者与第三方统计人员三分离的施盲方法,仅患者和雷火灸操作者了解具体分组,第三方统计人员不了解具体分组。在填写病例记录表时,治疗组与对照组分别以A和B表示,以确保不参与试验的第三方统计人员在进行数据统计处理时的客观性。在进行统计处理前,所有数据将均由专人进行保管,数据统计结束时揭盲。

Blinding:

This study will use the blindness method of separating patients, operators and third party statisticians. Only patients and thunder moxibustion operators know the specific group, and the third party statisticians do not know the specific group. When completing the case record form, the treatment group and the control group are expressed in A and B, respectively, to ensure the objectivity of the third-party statisticians who did not participate in the trial when performing the data statistical processing. Before statistical processing, all data will be kept by special personnel, and the blind will be uncovered at the end of data statistics.

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2024-07-10 17:07:07